O	O	0	11	Fludarabine	Fludarabine	B-NP	NN	O	4	NMOD	O
O	O	11	12	-	-	B-NP	HYPH	O	1	P	O
O	O	12	19	induced	induce	I-NP	VBN	O	4	NMOD	O
O	O	20	37	immunosuppression	immunosuppression	I-NP	NN	O	5	SUB	O
O	O	38	40	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	41	51	associated	associate	I-VP	VBN	O	5	VC	O
O	O	52	56	with	with	B-PP	IN	O	6	VMOD	O
O	O	57	67	inhibition	inhibition	B-NP	NN	O	7	PMOD	O
O	O	68	70	of	of	B-PP	IN	O	8	NMOD	O
T1	B-Protein	71	76	STAT1	STAT1	B-NP	NN	B-protein	11	NMOD	B-protein
O	O	77	86	signaling	signaling	I-NP	NN	O	9	PMOD	O
O	O	86	87	.	.	O	.	O	5	P	O

O	O	89	100	Fludarabine	Fludarabine	B-NP	NN	O	2	SUB	O
O	O	101	103	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	104	105	a	a	B-NP	DT	O	5	NMOD	O
O	O	106	116	nucleoside	nucleoside	I-NP	NN	O	5	NMOD	O
O	O	117	123	analog	analog	I-NP	NN	O	2	PRD	O
O	O	124	128	used	use	B-VP	VBN	O	5	NMOD	O
O	O	129	131	in	in	B-PP	IN	O	6	VMOD	O
O	O	132	135	the	the	B-NP	DT	O	9	NMOD	O
O	O	136	145	treatment	treatment	I-NP	NN	O	7	PMOD	O
O	O	146	148	of	of	B-PP	IN	O	9	NMOD	O
O	O	149	160	hematologic	hematologic	B-NP	JJ	O	12	NMOD	O
O	O	161	173	malignancies	malignancy	I-NP	NNS	O	10	PMOD	O
O	O	174	178	that	that	B-NP	WDT	O	12	NMOD	O
O	O	179	182	can	can	B-VP	MD	O	13	SBAR	O
O	O	183	189	induce	induce	I-VP	VB	O	14	VC	O
O	O	190	196	severe	severe	B-NP	JJ	O	18	AMOD	O
O	O	197	200	and	and	I-NP	CC	O	18	AMOD	O
O	O	201	210	prolonged	prolonged	I-NP	JJ	O	19	NMOD	O
O	O	211	228	immunosuppression	immunosuppression	I-NP	NN	O	15	OBJ	O
O	O	228	229	.	.	O	.	O	2	P	O

O	O	230	238	Although	Although	B-SBAR	IN	O	14	VMOD	O
O	O	239	241	it	it	B-NP	PRP	O	3	SUB	O
O	O	242	245	can	can	B-VP	MD	O	1	SBAR	O
O	O	246	248	be	be	I-VP	VB	O	3	VC	O
O	O	249	261	incorporated	incorporate	I-VP	VBN	O	4	VC	O
O	O	262	266	into	into	B-PP	IN	O	5	VMOD	O
O	O	267	270	the	the	B-NP	DT	O	8	NMOD	O
O	O	271	274	DNA	DNA	I-NP	NN	O	6	PMOD	O
O	O	275	277	of	of	B-PP	IN	O	8	NMOD	O
O	O	278	286	dividing	divide	B-VP	VBG	B-cell_type	11	NMOD	B-cell_type
O	O	287	292	cells	cell	B-NP	NNS	I-cell_type	9	PMOD	I-cell_type
O	O	292	293	,	,	O	,	O	14	P	O
O	O	294	305	fludarabine	fludarabine	B-NP	NN	O	14	SUB	O
O	O	306	308	is	be	B-VP	VBZ	O	29	VMOD	O
O	O	309	313	also	also	B-ADVP	RB	O	14	VMOD	O
O	O	314	315	a	a	B-NP	DT	O	18	NMOD	O
O	O	316	322	potent	potent	I-NP	JJ	O	18	NMOD	O
O	O	323	332	inhibitor	inhibitor	I-NP	NN	O	14	PRD	O
O	O	333	335	of	of	B-PP	IN	O	18	NMOD	O
O	O	336	341	cells	cell	B-NP	NNS	O	19	PMOD	O
O	O	342	346	with	with	B-PP	IN	O	18	NMOD	O
O	O	347	348	a	a	B-NP	DT	O	25	NMOD	O
O	O	349	352	low	low	I-NP	JJ	O	25	NMOD	O
O	O	353	359	growth	growth	I-NP	NN	O	25	NMOD	O
O	O	360	368	fraction	fraction	I-NP	NN	O	21	PMOD	O
O	O	368	369	,	,	O	,	O	29	P	O
O	O	370	374	thus	thus	B-ADVP	RB	O	29	VMOD	O
O	O	375	377	it	it	B-NP	PRP	O	29	SUB	O
O	O	378	382	must	must	B-VP	MD	O	0	ROOT	O
O	O	383	387	have	have	I-VP	VB	O	29	VC	O
O	O	388	393	other	other	B-NP	JJ	O	32	NMOD	O
O	O	394	404	mechanisms	mechanism	I-NP	NNS	O	30	OBJ	O
O	O	405	407	of	of	B-PP	IN	O	32	NMOD	O
O	O	408	414	action	action	B-NP	NN	O	33	PMOD	O
O	O	414	415	.	.	O	.	O	29	P	O

T2	B-Protein	416	421	STAT1	STAT1	B-NP	NN	B-protein	18	SUB	B-protein
O	O	421	422	,	,	O	,	O	1	P	O
O	O	423	428	which	which	B-NP	WDT	O	1	NMOD	O
O	O	429	431	is	be	B-VP	VBZ	O	3	SBAR	O
O	O	432	441	activated	activate	I-VP	VBN	O	4	VC	O
O	O	442	444	in	in	B-PP	IN	O	5	VMOD	O
O	O	445	453	response	response	B-NP	NN	O	6	PMOD	O
O	O	454	456	to	to	B-PP	TO	O	7	NMOD	O
O	O	457	461	many	many	B-NP	JJ	O	8	PMOD	O
O	O	462	472	lymphocyte	lymphocyte	I-NP	NN	O	13	NMOD	O
O	O	472	473	-	-	I-NP	HYPH	O	10	P	O
O	O	473	483	activating	activate	B-VP	VBG	O	13	NMOD	O
O	O	484	493	cytokines	cytokine	B-NP	NNS	B-protein	9	NMOD	B-protein
O	O	494	503	including	include	B-PP	VBG	O	9	NMOD	O
O	O	504	507	the	the	B-NP	DT	O	16	NMOD	O
O	O	508	519	interferons	interferon	I-NP	NNS	B-protein	14	PMOD	B-protein
O	O	519	520	,	,	O	,	O	1	P	O
O	O	521	523	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	524	533	essential	essential	B-ADJP	JJ	O	18	PRD	O
O	O	534	537	for	for	B-PP	IN	O	19	AMOD	O
O	O	538	542	cell	cell	B-NP	NN	O	24	NMOD	O
O	O	542	543	-	-	B-NP	HYPH	O	24	NMOD	O
O	O	543	551	mediated	mediate	I-NP	VBN	O	24	NMOD	O
O	O	552	560	immunity	immunity	I-NP	NN	O	20	PMOD	O
O	O	560	561	,	,	O	,	O	18	P	O
O	O	562	564	as	as	B-SBAR	IN	O	18	VMOD	O
O	O	565	568	the	the	B-NP	DT	O	28	NMOD	O
O	O	569	576	absence	absence	I-NP	NN	O	32	SUB	O
O	O	577	579	of	of	B-PP	IN	O	28	NMOD	O
O	O	580	584	this	this	B-NP	DT	O	31	NMOD	O
O	O	585	592	protein	protein	I-NP	NN	O	29	PMOD	O
O	O	593	595	is	be	B-VP	VBZ	O	26	SBAR	O
O	O	596	606	associated	associate	I-VP	VBN	O	32	VC	O
O	O	607	611	with	with	B-PP	IN	O	33	VMOD	O
O	O	612	621	prominent	prominent	B-NP	JJ	O	36	NMOD	O
O	O	622	629	defects	defect	I-NP	NNS	O	34	PMOD	O
O	O	630	632	in	in	B-PP	IN	O	36	NMOD	O
O	O	633	636	the	the	B-NP	DT	O	39	NMOD	O
O	O	637	644	ability	ability	I-NP	NN	O	37	PMOD	O
O	O	645	647	to	to	B-VP	TO	O	41	VMOD	O
O	O	648	655	control	control	I-VP	VB	O	39	NMOD	O
O	O	656	661	viral	viral	B-NP	JJ	O	43	NMOD	O
O	O	662	672	infections	infection	I-NP	NNS	O	41	OBJ	O
O	O	672	673	.	.	O	.	O	18	P	O

O	O	674	678	Here	Here	B-ADVP	RB	O	3	VMOD	O
O	O	679	681	we	we	B-NP	PRP	O	3	SUB	O
O	O	682	686	show	show	B-VP	VBP	O	0	ROOT	O
O	O	687	691	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	692	703	fludarabine	fludarabine	B-NP	NN	O	12	NMOD	O
O	O	703	704	,	,	B-PP	,	O	12	P	O
O	O	705	708	but	but	I-PP	CC	O	12	NMOD	O
O	O	709	712	not	not	O	RB	O	7	DEP	O
O	O	713	716	the	the	B-NP	DT	O	12	NMOD	O
O	O	717	734	immunosuppressant	immunosuppressant	I-NP	JJ	O	12	NMOD	O
O	O	735	747	cyclosporine	cyclosporine	I-NP	NN	O	12	NMOD	O
O	O	748	749	A	A	I-NP	NN	O	14	SUB	O
O	O	749	750	,	,	O	,	O	12	P	O
O	O	751	759	inhibits	inhibit	B-VP	VBZ	O	4	SBAR	O
O	O	760	763	the	the	B-NP	DT	O	14	OBJ	O
O	O	764	772	cytokine	cytokine	I-NP	NN	B-protein	15	DEP	B-protein
O	O	772	773	-	-	B-VP	HYPH	O	16	NMOD	O
O	O	773	780	induced	induce	B-NP	VBN	O	19	NMOD	O
O	O	781	791	activation	activation	I-NP	NN	O	17	OBJ	O
O	O	792	794	of	of	B-PP	IN	O	19	NMOD	O
T3	B-Protein	795	800	STAT1	STAT1	B-NP	NN	B-protein	27	NMOD	B-protein
O	O	801	804	and	and	I-NP	CC	O	27	NMOD	O
T4	B-Protein	805	810	STAT1	STAT1	I-NP	NN	B-protein	27	NMOD	B-protein
O	O	810	811	-	-	B-NP	HYPH	O	27	NMOD	O
O	O	811	820	dependent	dependent	I-NP	JJ	O	27	NMOD	O
O	O	821	825	gene	gene	I-NP	NN	O	27	NMOD	O
O	O	826	839	transcription	transcription	I-NP	NN	O	20	PMOD	O
O	O	840	842	in	in	B-PP	IN	O	27	NMOD	O
O	O	843	849	normal	normal	B-NP	JJ	B-cell_type	33	NMOD	B-cell_type
O	O	850	857	resting	rest	I-NP	VBG	I-cell_type	32	AMOD	I-cell_type
O	O	858	860	or	or	I-NP	CC	I-cell_type	32	AMOD	I-cell_type
O	O	861	870	activated	activate	I-NP	VBN	I-cell_type	33	NMOD	I-cell_type
O	O	871	882	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	28	PMOD	I-cell_type
O	O	882	883	.	.	O	.	O	3	P	O

O	O	884	895	Fludarabine	Fludarabine	B-NP	NN	O	2	SUB	O
O	O	896	902	caused	cause	B-VP	VBD	O	0	ROOT	O
O	O	903	904	a	a	B-NP	DT	O	5	NMOD	O
O	O	905	913	specific	specific	I-NP	JJ	O	5	NMOD	O
O	O	914	923	depletion	depletion	I-NP	NN	O	2	OBJ	O
O	O	924	926	of	of	B-PP	IN	O	5	NMOD	O
T5	B-Protein	927	932	STAT1	STAT1	B-NP	NN	B-protein	8	NMOD	B-protein
O	O	933	940	protein	protein	I-NP	NN	I-protein	6	PMOD	I-protein
O	O	941	942	(	(	O	(	O	12	DEP	O
O	O	942	945	and	and	O	CC	O	11	NMOD	O
O	O	946	950	mRNA	mRNA	B-NP	NN	B-RNA	12	DEP	B-RNA
O	O	950	951	)	)	O	)	O	8	NMOD	O
O	O	952	955	but	but	B-PP	CC	O	6	PMOD	O
O	O	956	959	not	not	B-PP	RB	O	15	PMOD	O
O	O	960	962	of	of	I-PP	IN	O	6	PMOD	O
O	O	963	968	other	other	B-NP	JJ	O	17	NMOD	O
O	O	969	974	STATs	STAT	I-NP	NNS	B-protein	15	PMOD	B-protein
O	O	974	975	.	.	O	.	O	2	P	O

O	O	976	980	This	This	B-NP	DT	O	2	NMOD	O
O	O	981	985	loss	loss	I-NP	NN	O	5	SUB	O
O	O	986	988	of	of	B-PP	IN	O	2	NMOD	O
T6	B-Protein	989	994	STAT1	STAT1	B-NP	NN	B-protein	3	PMOD	B-protein
O	O	995	998	was	be	B-VP	VBD	O	0	ROOT	O
O	O	999	1003	also	also	I-VP	RB	O	5	VMOD	O
O	O	1004	1008	seen	see	I-VP	VBN	O	5	VC	O
O	O	1009	1011	in	in	B-PP	IN	O	7	VMOD	O
O	O	1012	1017	cells	cell	B-NP	NNS	O	8	PMOD	O
O	O	1018	1022	from	from	B-PP	IN	O	9	NMOD	O
O	O	1023	1031	patients	patient	B-NP	NNS	O	10	PMOD	O
O	O	1032	1039	treated	treat	B-VP	VBN	O	11	NMOD	O
O	O	1040	1044	with	with	B-PP	IN	O	12	VMOD	O
O	O	1045	1056	fludarabine	fludarabine	B-NP	NN	O	13	PMOD	O
O	O	1057	1059	in	in	B-ADVP	FW	O	12	VMOD	O
O	O	1060	1064	vivo	vivo	I-ADVP	FW	O	15	AMOD	O
O	O	1064	1065	.	.	O	.	O	5	P	O

O	O	1066	1071	Brief	Brief	B-NP	JJ	O	2	NMOD	O
O	O	1072	1080	exposure	exposure	I-NP	NN	O	5	SUB	O
O	O	1081	1083	to	to	B-PP	TO	O	2	NMOD	O
O	O	1084	1095	fludarabine	fludarabine	B-NP	NN	O	3	PMOD	O
O	O	1096	1099	led	lead	B-VP	VBD	O	0	ROOT	O
O	O	1100	1102	to	to	B-PP	TO	O	5	VMOD	O
O	O	1103	1104	a	a	B-NP	DT	O	9	NMOD	O
O	O	1105	1114	sustained	sustained	I-NP	JJ	O	9	NMOD	O
O	O	1115	1119	loss	loss	I-NP	NN	O	6	PMOD	O
O	O	1120	1122	of	of	B-PP	IN	O	9	NMOD	O
T7	B-Protein	1123	1128	STAT1	STAT1	B-NP	NN	B-protein	10	PMOD	B-protein
O	O	1128	1129	,	,	O	,	O	5	P	O
O	O	1130	1139	analogous	analogous	B-ADJP	JJ	O	5	VMOD	O
O	O	1140	1142	to	to	B-PP	TO	O	13	AMOD	O
O	O	1143	1146	the	the	B-NP	DT	O	17	NMOD	O
O	O	1147	1156	prolonged	prolonged	I-NP	JJ	O	17	NMOD	O
O	O	1157	1163	period	period	I-NP	NN	O	14	PMOD	O
O	O	1164	1166	of	of	B-PP	IN	O	17	NMOD	O
O	O	1167	1184	immunosuppression	immunosuppression	B-NP	NN	O	18	PMOD	O
O	O	1185	1192	induced	induce	B-VP	VBN	O	19	NMOD	O
O	O	1193	1195	by	by	B-PP	IN	O	20	VMOD	O
O	O	1196	1204	exposure	exposure	B-NP	NN	O	21	PMOD	O
O	O	1205	1207	to	to	B-PP	TO	O	22	NMOD	O
O	O	1208	1211	the	the	B-NP	DT	O	25	NMOD	O
O	O	1212	1216	drug	drug	I-NP	NN	O	23	PMOD	O
O	O	1217	1219	in	in	B-ADVP	FW	O	20	VMOD	O
O	O	1220	1224	vivo	vivo	I-ADVP	FW	O	26	AMOD	O
O	O	1224	1225	.	.	O	.	O	5	P	O

O	O	1226	1230	Thus	Thus	B-ADVP	RB	O	4	VMOD	O
O	O	1230	1231	,	,	O	,	O	4	P	O
T8	B-Protein	1232	1237	STAT1	STAT1	B-NP	NN	B-protein	4	SUB	B-protein
O	O	1238	1241	may	may	B-VP	MD	O	0	ROOT	O
O	O	1242	1244	be	be	I-VP	VB	O	4	VC	O
O	O	1245	1246	a	a	B-NP	DT	O	8	NMOD	O
O	O	1247	1253	useful	useful	I-NP	JJ	O	8	NMOD	O
O	O	1254	1260	target	target	I-NP	NN	O	5	PRD	O
O	O	1261	1263	in	in	B-PP	IN	O	5	VMOD	O
O	O	1264	1267	the	the	B-NP	DT	O	11	NMOD	O
O	O	1268	1279	development	development	I-NP	NN	O	9	PMOD	O
O	O	1280	1282	of	of	B-PP	IN	O	11	NMOD	O
O	O	1283	1286	new	new	B-NP	JJ	O	17	NMOD	O
O	O	1287	1304	immunosuppressive	immunosuppressive	I-NP	JJ	O	16	AMOD	O
O	O	1305	1308	and	and	I-NP	CC	O	16	AMOD	O
O	O	1309	1323	antineoplastic	antineoplastic	I-NP	JJ	O	17	NMOD	O
O	O	1324	1330	agents	agent	I-NP	NNS	O	12	PMOD	O
O	O	1330	1331	.	.	O	.	O	4	P	O
